4.7 Article

β2-Glycoprotein I: a novel component of innate immunity

期刊

BLOOD
卷 117, 期 25, 页码 6939-6947

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-12-325951

关键词

-

资金

  1. Swedish Medical Research Council [2008-7480]
  2. Foundations of Crafoord
  3. Greta och Johan Kock's stiftelser
  4. Alfred Osterlund's stiftelse
  5. Konung Gustav V's 80-Arsfond
  6. Swedish Society for Medicine
  7. Medical Faculty, Lund University
  8. Netherlands Organization for Scientific Research (ZonMW)
  9. Academic Medical Center
  10. Netherlands Heart Foundation [2006T053]

向作者/读者索取更多资源

Sepsis is a systemic host response to invasive infection by bacteria. Despite treatment with antibiotics, current mortality rates are in the range of 20%-25%, which makes sepsis the most important cause of death in intensive care. Gram-negative bacteria are a prominent cause of sepsis. Lipopolysaccharide (LPS), one of the major constituents of the outer membrane of Gram-negative bacteria, plays a major role in activating the host's immune response by binding to monocytes and other cells. Several proteins are involved in neutralization and clearance of LPS from the bloodstream. Here, we provide evidence that beta(2)-glycoprotein I (beta(2)GPI) is a scavenger of LPS. In vitro, beta(2)GPI inhibited LPS-induced expression of tissue factor and IL-6 from monocytes and endothelial cells. Binding of beta(2)GPI to LPS caused a conformational change in beta(2)GPI that led to binding of the beta(2)GPI-LPS complex to monocytes and ultimately clearance of this complex. Furthermore, plasma levels of beta(2)GPI were inversely correlated with temperature rise and the response of inflammatory markers after a bolus injection of LPS in healthy individuals. Together, these observations provide evidence that beta(2)GPI is involved in the neutralization and clearance of LPS and identify beta(2)GPI as a component of innate immunity. (Blood. 2011;117(25):6939-6947)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据